Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89

R. Sciuto, C. L. Maini, A. Tofani, C. Fiumara, M. G. Scelsa, M. Broccatelli

Research output: Contribution to journalArticle

Abstract

Strontium-89 (89Sr) is currently used for the treatment of painful bone metastases. This study reports the use of low-dose carboplatin as a radiosensitizer in 89Sr radioisotope therapy. The study design comprised two groups: 15 patients treated with 89Sr (148 MBq) followed by carboplatin (100 mg m-2 at 7 and 21 days) and 15 patients treated with 89Sr alone. Their pain response was assessed 8 weeks post-injection. Follow-up was continued for up to 1 year in the survivors. Twenty-seven patients were evaulable. A pain response was observed in 20 of 27 (74%) patients. The pain response in the patients treated with 89Sr and carboplatin was clearly superior to that seen in the patients treated with 89Sr alone (P = 0.025), whereas survival was only marginally better in the combined treatment group (8.1 vs 5.7 months, P = 0.19). No clinically significant adverse effects or myelosuppression by carboplatin were observed. Low-dose carboplatin enhances the effects of 89Sr radioisotope therapy on pain from bone metastases.

Original languageEnglish
Pages (from-to)799-804
Number of pages6
JournalNuclear Medicine Communications
Volume17
Issue number9
Publication statusPublished - 1996

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Fingerprint Dive into the research topics of 'Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89'. Together they form a unique fingerprint.

  • Cite this

    Sciuto, R., Maini, C. L., Tofani, A., Fiumara, C., Scelsa, M. G., & Broccatelli, M. (1996). Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89. Nuclear Medicine Communications, 17(9), 799-804.